Sofwave Medical, which develops and markets systems for medical aesthetic treatments, released its financial results this morning for the third quarter of 2026, reporting revenue growth and a significant improvement in profitability.
The company's revenue totaled $28.5 million, up 35% from $21.1 million in the corresponding quarter last year. Net profit surged to approximately $4.1 million, compared with approximately $982 thousand in the corresponding period. Operating profit nearly tripled to $4.42 million.
One of the prominent growth drivers in the quarter was recurring revenue from use of the company's systems, which grew 60% to $13.3 million, approximately 47% of total revenue. At the same time, the gross profit margin rose to 76.6%, and the company recorded positive cash flow of approximately $2.8 million from operating activities.
Establishing a foothold in China
Alongside its financial results, Sofwave reported progress in its operations in China. After receiving regulatory approval to market its products in the country in September, the company received an initial order for 70 systems from local distributor HTDK. Ten systems were delivered during the third quarter, and the remaining 60 systems are expected to be delivered in the fourth quarter. The company did not disclose the financial value of the order.
Looking at the first nine months of the year, Sofwave's revenue totaled $82.9 million, up 41% from the corresponding period in 2025. Net profit during this period reached $7.9 million, compared with approximately $1.4 million in the first nine months of last year.











